Evaluation of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Glaucoma Patients
NCT ID: NCT05181046
Last Updated: 2023-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
420 participants
INTERVENTIONAL
2021-11-06
2022-12-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial
NCT05844384
Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension
NCT04910100
Safety and Efficacy of Travoprost/Timolol BAC-free
NCT00760539
Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension
NCT01216943
Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)
NCT01254604
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard eyedrops of 0.5% timolol maleate
Participants randomized to this arm will receive one standard drop of 0.5% timolol maleate in each eye.
Original eyedrop bottle/No Nanodropper
The original eyedrop bottle dispenses standard eyedrops.
Nanodropper-mediated microdrops of 0.5% timolol maleate
Participants randomized to this arm will receive one microdrop of 0.5% timolol maleate in each eye. Microdrops will be dispensed from bottles with installed Nanodropper adaptors.
Nanodropper adaptor
The Nanodropper adaptor is a sterile medical device that reduces the size of administered eyedrops by coupling to the original bottle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nanodropper adaptor
The Nanodropper adaptor is a sterile medical device that reduces the size of administered eyedrops by coupling to the original bottle.
Original eyedrop bottle/No Nanodropper
The original eyedrop bottle dispenses standard eyedrops.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Recent diagnosis of primary OAG or OHT
* Treatment-naive (not currently using ophthalmic medication)
* Baseline IOP between 21-35 mm Hg
* Corrected Snellen visual acuity of 6/60 or better in each eye
Exclusion Criteria
* A recent history (within the past 6 months) of ocular trauma, infection, or uveitis
* Baseline IOP \<21 mm Hg or \>35 mm Hg
* History of cardiovascular, pulmonary, cerebrovascular, or chronic renal disease
* History of borderline or uncontrolled systemic arterial hypertension
* Use of any systemic α-agonist or β-blocker within 30 days of study commencement
* History of receiving general anesthesia within the previous 30 days
* Pregnant women and nursing mothers
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aravind Eye Care System
OTHER
Nanodropper, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jennifer Steger, PhD
Role: STUDY_DIRECTOR
Nanodropper, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aravind Eye Hospital
Madurai, , India
Aravind Eye Hospital
Puducherry, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
nano001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.